Title:
ANTIBODY AGAINST PANCREATIC CANCER STEM CELLS
Document Type and Number:
WIPO Patent Application WO/2022/215679
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide an antibody against pancreatic cancer stem cells. This antibody against pancreatic cancer stem cells includes a heavy chain variable region including heavy chain CDRs described as HCDR1-HCDR3, and a light chain variable region including light chain CDRs described as LCDR1-LCDR3, and has an ability to bind to pancreatic cancer stem cells, where HCDR1 has an amino acid sequence located at positions 26-35 in SEQ ID NO: 1 or a sequence analogous thereto, HCDR2 has a sequence located at positions 47-65 in SEQ ID NO: 1 or a sequence analogous thereto, HCDR3 has a sequence located at positions 96-104 in SEQ ID NO: 1 or a sequence analogous thereto, LCDR1 has a sequence located at positions 24-34 in SEQ ID NO: 2 or a sequence analogous thereto, LCDR2 has a sequence located at positions 46-56 in SEQ ID NO: 2 or a sequence analogous thereto, and LCDR3 has a sequence located at positions 89-96 in SEQ ID NO: 2 or a sequence analogous thereto.
More Like This:
Inventors:
TACHIBANA TARO (JP)
IHARA KANICHIRO (JP)
HORI YUICHI (JP)
SHIMIZU KAZUYA (JP)
IHARA KANICHIRO (JP)
HORI YUICHI (JP)
SHIMIZU KAZUYA (JP)
Application Number:
PCT/JP2022/017037
Publication Date:
October 13, 2022
Filing Date:
April 04, 2022
Export Citation:
Assignee:
UNIV OSAKA PUBLIC CORP (JP)
UNIV KOBE NAT UNIV CORP (JP)
UNIV KOBE NAT UNIV CORP (JP)
International Classes:
C12N15/13; A61K39/395; A61P1/18; A61P35/00; A61P43/00; C07K16/28; C07K16/32; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08; G01N33/574
Domestic Patent References:
| WO2005080432A2 | 2005-09-01 |
Foreign References:
| JP2020524527A | 2020-08-20 | |||
| US20120095192A1 | 2012-04-19 | |||
| KR20200132110A | 2020-11-25 | |||
| US4816567A | 1989-03-28 |
Other References:
SUN LIXIN; YU LONG; XIE YIBIN; MO WENXIU; LIU HUIQI; YANG ZHIHUA; RAN YULIANG; SUN LICHAO: "Screen and identification of monoclonal antibody against pancreatic cancer stem cells", JOURNAL OF MODERN ONCOLOGY, vol. 22, no. 7, 1 January 2014 (2014-01-01), pages 1492 - 1496, XP009540281, ISSN: 1672-4992
CIOFFI MICHELE, DORADO JORGE, BAEUERLE PATRICK A., HEESCHEN CHRISTOPHER: "EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 2, 15 January 2012 (2012-01-15), US, pages 465 - 474, XP055976445, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-1270
BORST P.: "Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?", OPEN BIOL, vol. 2, 2012, pages 120066
HOLOHAN C.VAN SCHAEYBROECK, S.LONGLEY, D. B.JOHNSTON, P.G.: "Cancer drug resistance: an evolving paradigm", NAT. REV. CANCER., vol. 13, 2013, pages 714 - 726, XP055252550, DOI: 10.1038/nrc3599
DIEHN MCHO RWLOBO NAKALISKY TDORIE MJ ET AL.: "Association of reactive oxygen species levels and radioresistance in cancer stem cells", NATURE, vol. 458, 2009, pages 780 - 783
XIAOXIAN LIMICHAEL T. LEWISJIAN HUANGCAROLINA GUTIERREZC. KENT OSBORNE ET AL.: "Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy", J. NATL. CANCER INST., vol. 100, 2008, pages 672 - 679
SHIDENG BAOQIULIAN WULROGER E. MCLENDONYUELING HAOQING SHI ET AL.: "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response", NATURE, vol. 444, 2006, pages 756 - 760, XP055200572, DOI: 10.1038/nature05236
EDUARD BATLLEHANS CLEVERS: "Cancer stem cells revisited", NAT. MED., vol. 23, 2017, pages 1124 - 1134, XP055840734, DOI: 10.1038/nm.4409
NAOKO TAKEBELUCIO MIELEPAMELA JO HARRISWOONDONG JEONGHIDEAKI BANDO ET AL.: "Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update", NAT. REV. CLIN. ONCOL., vol. 12, 2015, pages 445 - 464, XP055605624, DOI: 10.1038/nrclinonc.2015.61
LASZLO G.S.ESTEY E.H.WALTER R.B.: "The past and future of CD33 as therapeutic target in acute myeloid leukemia", BLOOD REV, vol. 28, 2014, pages 143 - 153, XP055940017, DOI: 10.1016/j.blre.2014.04.001
BIOINFORMATICS, vol. 32, 2016, pages 298 - 300
DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
NUCLEIC ACIDS RES, vol. 40, 2012, pages W521 - 4
PLOS COMPUT BIOL, vol. 8, no. 2, 2012, pages e1002388
HASHIMOTO-GOTOH T. ET AL., GENE, vol. 152, 1995, pages 271 - 275
ZOLLER MJ ET AL., METHODS ENZYMOL, vol. 100, 1983, pages 468 - 500
KRAMER W. ET AL., NUCLEIC ACIDS RES, vol. 12, 1984, pages 9441 - 9456
KRAMER W. ET AL., METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367
KUNKEL TA, PROC NATL ACAD SCI USA, vol. 82, 1985, pages 488 - 492
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250
KOHLER GMILSTEIN C, NATURE, vol. 256, no. 5517, 7 August 1975 (1975-08-07), pages 495 - 497
CLACKSON ET AL., NATURE, vol. 352, no. 6336, 15 August 1991 (1991-08-15), pages 624 - 628
MARKS ET AL., J MOL BIOL, vol. 222, no. 3, 5 December 1991 (1991-12-05), pages 581 - 597
"Protein Experiment Handbook", 2003, YODOSHA CO., LTD., pages: 92 - 96
SATO, K. ET AL., CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
SHIMIZU K., NISHIYAMA T., HORI Y.: "Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells", PANCREAS, vol. 46, 2017, pages 268 - 275
CHRISTINE M F.CHARLOTTE K.: "Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy", BREAST CANCER RESEARCH, vol. 10, 2008, pages R 25
CIOFFI MICHELE, DORADO JORGE, BAEUERLE PATRICK A., HEESCHEN CHRISTOPHER: "EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 2, 15 January 2012 (2012-01-15), US, pages 465 - 474, XP055976445, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-1270
BORST P.: "Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?", OPEN BIOL, vol. 2, 2012, pages 120066
HOLOHAN C.VAN SCHAEYBROECK, S.LONGLEY, D. B.JOHNSTON, P.G.: "Cancer drug resistance: an evolving paradigm", NAT. REV. CANCER., vol. 13, 2013, pages 714 - 726, XP055252550, DOI: 10.1038/nrc3599
DIEHN MCHO RWLOBO NAKALISKY TDORIE MJ ET AL.: "Association of reactive oxygen species levels and radioresistance in cancer stem cells", NATURE, vol. 458, 2009, pages 780 - 783
XIAOXIAN LIMICHAEL T. LEWISJIAN HUANGCAROLINA GUTIERREZC. KENT OSBORNE ET AL.: "Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy", J. NATL. CANCER INST., vol. 100, 2008, pages 672 - 679
SHIDENG BAOQIULIAN WULROGER E. MCLENDONYUELING HAOQING SHI ET AL.: "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response", NATURE, vol. 444, 2006, pages 756 - 760, XP055200572, DOI: 10.1038/nature05236
EDUARD BATLLEHANS CLEVERS: "Cancer stem cells revisited", NAT. MED., vol. 23, 2017, pages 1124 - 1134, XP055840734, DOI: 10.1038/nm.4409
NAOKO TAKEBELUCIO MIELEPAMELA JO HARRISWOONDONG JEONGHIDEAKI BANDO ET AL.: "Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update", NAT. REV. CLIN. ONCOL., vol. 12, 2015, pages 445 - 464, XP055605624, DOI: 10.1038/nrclinonc.2015.61
LASZLO G.S.ESTEY E.H.WALTER R.B.: "The past and future of CD33 as therapeutic target in acute myeloid leukemia", BLOOD REV, vol. 28, 2014, pages 143 - 153, XP055940017, DOI: 10.1016/j.blre.2014.04.001
BIOINFORMATICS, vol. 32, 2016, pages 298 - 300
DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
NUCLEIC ACIDS RES, vol. 40, 2012, pages W521 - 4
PLOS COMPUT BIOL, vol. 8, no. 2, 2012, pages e1002388
HASHIMOTO-GOTOH T. ET AL., GENE, vol. 152, 1995, pages 271 - 275
ZOLLER MJ ET AL., METHODS ENZYMOL, vol. 100, 1983, pages 468 - 500
KRAMER W. ET AL., NUCLEIC ACIDS RES, vol. 12, 1984, pages 9441 - 9456
KRAMER W. ET AL., METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367
KUNKEL TA, PROC NATL ACAD SCI USA, vol. 82, 1985, pages 488 - 492
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250
KOHLER GMILSTEIN C, NATURE, vol. 256, no. 5517, 7 August 1975 (1975-08-07), pages 495 - 497
CLACKSON ET AL., NATURE, vol. 352, no. 6336, 15 August 1991 (1991-08-15), pages 624 - 628
MARKS ET AL., J MOL BIOL, vol. 222, no. 3, 5 December 1991 (1991-12-05), pages 581 - 597
"Protein Experiment Handbook", 2003, YODOSHA CO., LTD., pages: 92 - 96
SATO, K. ET AL., CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
SHIMIZU K., NISHIYAMA T., HORI Y.: "Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells", PANCREAS, vol. 46, 2017, pages 268 - 275
CHRISTINE M F.CHARLOTTE K.: "Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy", BREAST CANCER RESEARCH, vol. 10, 2008, pages R 25
Attorney, Agent or Firm:
TANAKA, Junya et al. (JP)
Download PDF:
Previous Patent: CELLULOSE ESTER COMPOSITION AND MOLDED ARTICLE
Next Patent: PLASMA TREATMENT DEVICE AND ELECTRODE MECHANISM
Next Patent: PLASMA TREATMENT DEVICE AND ELECTRODE MECHANISM